Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 6
Submit an article Journal homepage
527
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma

Frank HertingRoche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Munich, Germany; View further author information
,
Thomas FriessRoche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Munich, Germany; View further author information
,
Pablo UmañaRoche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Zurich, Switzerland; View further author information
,
Steven MiddletonRoche Pharmaceutical Research and Early Development, Roche Innovation Center New York, New York, USAView further author information
&
Christian KleinRoche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Zurich, Switzerland; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-7594-7280View further author information
ORCID Icon
Pages 1482-1485 | Received 03 Apr 2017, Accepted 30 Aug 2017, Published online: 15 Sep 2017

References

  • RITUXAN prescribing information [Internet]. 2010 [cited 2016 Sep 28]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf
  • Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. JCO. 2015;33:2516–2522.
  • Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393–4402.
  • Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12:2031–2042.
  • Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17:1081–1093.
  • Cheson BD, Trněný M, Bouabdallah K, et al. Obinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: updated results of the GADOLIN study. Blood. 2016;128:615.
  • Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101–1110.
  • Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29:1602–1604.
  • GAZYVA prescribing information [Internet]. 2016 [cited 2016 Sep 26]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125486s013lbl.pdf.
  • Marcus R, Davies A, Ando K, et al. Obinutuzumab-based induction and maintenance prolongs progression-free survival in patients with previously untreated follicular lymphoma: primary results of the randomized phase 3 GALLIUM study. Blood. 2016;128:6.
  • Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell cymphoma: final results from an open-label, randomized phase 3 study (GOYA). Blood. 2016;128:470.
  • Chiron D, Bellanger C, Papin A, et al. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood. 2016;128:2808–2818.
  • Sampath D, Herter S, Herting F, et al. Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101) and the novel Bcl-2 selective inhibitor GDC-0199 results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies. Blood. 2013;122:4412.
  • Herting F, Herter S, Friess T, et al. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2 selective antagonist idasanutlin (RG7388). Eur J Haematol. 2016;97:461–470.
  • Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–208.
  • Ding Q, Zhang Z, Liu JJ, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem. 2013;56:5979–5983.
  • Martinelli G, Pappayannidis C, Yee K, et al. Phase 1b results of idasanutlin + cytarabine (ARA-C) in acute myeloid leukemia (AML) patients (pts). Haematologica. 2016;S504.
  • Fischer K, Al-Sawaf O, Fink AM, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129:2702–2705.
  • Herting F, Friess T, Bader S, et al. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma. 2014;55:2151–5160.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.